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Background: Ultrafiltration is an alternative strategy to
diuretic therapy for the treatment of patients with acute
decompensated heart failure. Little is known about the efficacy
and safety of ultrafiltration in patients with acute decom-
pensated heart failure complicated by persistent congestion
and worsened renal function.
Methods: We randomly assigned a total of 188 patients
with acute decompensated heart failure, worsened renal
function, and persistent congestion to a strategy of stepped
pharmacologic therapy (94 patients) or ultrafiltration (94
patients). The primary endpoint was the bivariate change
from baseline in the serum creatinine level and body weight,
as assessed 96 h after random assignment. Patients were
followed for 60 days.
Results: Ultrafiltration was inferior to pharmacologic
therapy with respect to the bivariate end point of the change
in the serum creatinine level and body weight 96 h after
enrollment (p ¼ 0.003), owing primarily to an increase in the
creatinine level in the ultrafiltration group. At 96 h, the mean
change in the creatinine level was 0.04  0.53 mg per deci-
liter (3.5  46.9 mmol per liter) in the pharmacologic-therapy
group, as compared with þ0.23  0.70 mg per deciliter
(20.3  61.9 mmol per liter) in the ultrafiltration group
(p ¼ 0.003). There was no significant difference in weight loss
96 h after enrollment between patients in the pharmacologic-
therapy group and those in the ultrafiltration group (a loss of
5.5  5.1 kg [12.1  11.3 lb] and 5.7  3.9 kg [12.6  8.5 lb],
respectively; p ¼ 0.58). A higher percentage of patients in the
ultrafiltration group than in the pharmacologic-therapy group
had a serious adverse event (72% vs. 57%, p ¼ 0.03).
Conclusions: In a randomized trial involving patients
hospitalized for acute decompensated heart failure, worsened
renal function, and persistent congestion, the use of a stepped
pharmacologic-therapy algorithm was superior to a strategyof ultrafiltration for the preservation of renal function at 96 h,
with a similar amount of weight loss with the two approaches.
Ultrafiltration was associated with a higher rate of adverse
events.1. Perspective
Improving the quality of life is an important a goal in care of
patients of advance heart failure (HF) and is probably as
important as achieving mortality benefits. Recently published
CARRESSeHF1 trial addressed one such strategy. In this study,
ultrafiltration as an initial therapy was compared with I.V diu-
retics to achieve decongestion in patients admitted with
decompensated HF. Traditionally, escalating doses of diuretics
have been used to achieve desired results. However, newer
techniques like continuous veno-venous hemo-filtration have
been considered as a better initial therapy for achieving best
fluidvolumestatus, hypothesizing that slowandcontrolled loss
minimizes hemodynamic variations and neurohormonal acti-
vation. Earlier published UNLOAD2 study in the same subset of
patients showed that, dialysis produced greater weight and
fluid loss than diuretics and deceased 90-day resource uti-
lization for HF. The CARRESSeHF study had a meticulously
designed stepped up pharmacological care arm to tackle the
criticism of underdosing of diuretics in the UNLOAD study.
The pharmacological regimen consisted of bolus (half of his
daily outpatient oral loop diuretic dose) and continuous I.V
infusion of loop diuretic with provisional addition of thiazide
(metolazone). Assessment and escalation of diuretics was
done every 2 days, with addition of inotropes or vasodilators
depending on whether SBP was less or greater than
120 mm Hg, respectively.
The primary endpoint was net change in serum creatinine
and weight at 96 h. Results showed that similar weight loss
occurred in both groups (average about 5 kg) but statistically
significant increase in creatinine in ultrafiltration group.
There was no difference between the two groups in terms of
death or hospitalization for heart failure, but increased seri-
ous adverse events in the ultrafiltration group (72% vs 57%),
mainly due to renal failure, GI hemorrhage, and sepsis.
We believe that although, study is limited by non-blinded
design which may have introduced bias and also does not
provide a clear answer about safest andmost effective rates of
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dosing as advocated by the authors, is still a better initial
approach in diuretic responsive patients of decompensated
heart failure with persistent fluid overload.
The result of this trial should not undermine the utility of
ultrafiltration which still remains important treatment strat-
egy for diuretic unresponsive patients, rather sub serve for
conducting future studies with aim of finding adequate
ultrafiltration rates that may produce better results.r e f e r e n c e s
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Background: The multicenter PROTECT AF study (Watch-
man Left Atrial Appendage System for Embolic Protection in
Patients With Atrial Fibrillation) was conducted to determine
whether percutaneous left atrial appendage closure with a
filter device (Watchman) was noninferior to warfarin for
stroke prevention in atrial fibrillation.
Methods and results: Patients (n ¼ 707) with nonvalvular
atrial fibrillation and at least 1 risk factor (age >75 years,
hypertension, heart failure, diabetes, or prior stroke/transient
ischemic attack) were randomized to either the Watchman
device (n ¼ 463) or continued warfarin (n ¼ 244) in a 2:1 ratio.
After device implantation, warfarin was continued for z45
days, followed by clopidogrel for 4.5 months and lifelong
aspirin. Study discontinuation rates were 15.3% (71/463) and
22.5% (55/244) for the Watchman and warfarin groups,
respectively. The time in therapeutic range for the warfarin
group was 66%. The composite primary efficacy endpoint
included stroke, systemic embolism, and cardiovascular death,
and the primary analysis was by intention to treat. After 1588patient-years of follow-up (mean 2.3  1.1 years), the primary
efficacy event rates were 3.0% and 4.3% (percent per 100
patient-years) in the Watchman and warfarin groups, respec-
tively (relative risk, 0.71; 95% confidence interval, 0.44%e1.30%
per year), which met the criteria for noninferiority (probability
of noninferiority >0.999). There were more primary safety
events in the Watchman group (5.5% per year; 95% confidence
interval, 4.2%e7.1% per year) than in the control group (3.6%
per year; 95% confidence interval, 2.2%e5.3% per year; relative
risk, 1.53; 95% confidence interval, 0.95e2.70).
Conclusions: The “local” strategy of left atrial appendage
closure is noninferior to “systemic” anticoagulation with
warfarin. PROTECT AF has, for the first time, implicated the
left atrial appendage in the pathogenesis of stroke in atrial
fibrillation.1. Perspective
Balancing the benefits incurred by preventing stroke and sys-
temic embolism versus risks of major bleed has been the cor-
nerstone of developing effective anticoagulation strategies in
atrial fibrillation (AF). Recently approved oral anticoagulants
when compared to warfarin showed reduction in incidence of
stroke/embolism by 20e34%, ICH by 50e70%. However, rate of
major bleed has remained same with Dabigatran and Rivarox-
aban, and only Apixaban showing 30% reduction in such
events.1 The data from these trials highlight an important fact,
that an anticoagulant will always predispose an individual to
risk of bleeding and fatal hemorrhagic strokes no matter how
good it is. The recently published 2.3-year follow-up of the
PROTECTAF2 trial which looked at the strategy of occluding the
leftatrial appendage (LAA), isvery importantas itmarks thefirst
attempt of devisingways of preventing thromboembolic events
without subjecting individuals to excessive bleeding risk. In this
unblinded, multicenter study, 707 patients of nonvalvular AF
(CHADS2 score of1)were randomized to either theWatchman
device (n ¼ 463) or warfarin (n ¼ 244) in a 2:1 ratio. Patients in
device arm received warfarin for minimum of 45 days (more as
guided by TEE), dual antiplatelet for 4.5 months thereafter and
followed by lifelong aspirin. Eighty seven percent of patients
receiving the devicewere able to discontinuewarfarin at day 45
with number increasing to 95% by year-end.
The efficacy as assessed by composite of any stroke, car-
diovascular or unexplained death, or systemic embolism was
similar in both groups (3%/year in the device vs. 4.3%/year in
the controls) proving noninferiority.
Excessive bleeding and procedure related events occurred
more frequently in the device (5.5%) than in the control arm
(3.6%). While the incidence decreased over time in device
group it accrued in controls (post-procedure: 2.5%/year
versus 4.3%/year). Similarly, on long term follow-up lower
rate ofmajor bleeding in device group (RR 0.35) were observed.
The results indicate that after successful deployment, the
device proved to be superior to well controlled systemic
anticoagulation.
We believe that one of the biggest limitations of this study
is the relatively small number of patients enrolled as com-
pared to other studies involving new oral anticoagulants.
Drawing indirect conclusions seems inappropriate even
